Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory Cancer

Inclusion Criteria: * Diagnosis of metastatic or locally advanced non-hematological cancer * Patients with solid tumors refractory to therapy or for whom no therapy exists Exclusion Criteria: * Five or more prior chemotherapy lines for metastatic disease * Eastern Cooperative Oncology Group (ECOG) performance status \>2 * Patients having discontinued previous specific anti-cancer treatment * Patients who have not recovered from all toxic effects from previous specific anti-cancer treatment (excluding alopecia) * Patients with abnormal biological/hematological parameters, cardiac abnormalities or serious infection/intercurrent illness likely to jeopardize the patient's safety or the course of the protocol treatment * No adequate birth control methods The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.